ClariVest Asset Management LLC raised its holdings in shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 98.7% during the second quarter, HoldingsChannel.com reports. The firm owned 21,661 shares of the biotechnology company’s stock after acquiring an additional 10,761 shares during the quarter. ClariVest Asset Management LLC’s holdings in Enanta Pharmaceuticals were worth $2,510,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in ENTA. Matarin Capital Management LLC acquired a new position in Enanta Pharmaceuticals during the 1st quarter valued at about $18,084,000. Acadian Asset Management LLC lifted its position in Enanta Pharmaceuticals by 72.4% during the 2nd quarter. Acadian Asset Management LLC now owns 381,729 shares of the biotechnology company’s stock valued at $44,242,000 after purchasing an additional 160,344 shares during the period. Prudential Financial Inc. lifted its position in Enanta Pharmaceuticals by 134.2% during the 1st quarter. Prudential Financial Inc. now owns 217,190 shares of the biotechnology company’s stock valued at $17,573,000 after purchasing an additional 124,458 shares during the period. First Trust Advisors LP acquired a new position in Enanta Pharmaceuticals during the 2nd quarter valued at about $8,029,000. Finally, BlackRock Inc. lifted its position in Enanta Pharmaceuticals by 2.9% during the 2nd quarter. BlackRock Inc. now owns 2,433,000 shares of the biotechnology company’s stock valued at $281,985,000 after purchasing an additional 68,564 shares during the period. Institutional investors own 77.62% of the company’s stock.

A number of research firms have issued reports on ENTA. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $105.00 target price on the stock in a research report on Thursday, August 9th. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 22nd. UBS Group downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 8th. Oppenheimer began coverage on shares of Enanta Pharmaceuticals in a research report on Thursday, May 24th. They set a “buy” rating and a $135.00 target price on the stock. Finally, Roth Capital began coverage on shares of Enanta Pharmaceuticals in a research report on Wednesday, June 6th. They set a “buy” rating and a $133.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $107.60.

Shares of NASDAQ:ENTA opened at $90.95 on Wednesday. The company has a market capitalization of $1.76 billion, a P/E ratio of 21.55 and a beta of 0.88. Enanta Pharmaceuticals Inc has a fifty-two week low of $41.83 and a fifty-two week high of $127.77.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share for the quarter, missing analysts’ consensus estimates of $0.98 by ($0.01). The firm had revenue of $57.26 million during the quarter, compared to analyst estimates of $56.59 million. Enanta Pharmaceuticals had a net margin of 37.63% and a return on equity of 25.84%. research analysts predict that Enanta Pharmaceuticals Inc will post 3.56 earnings per share for the current fiscal year.

In related news, insider Jay R. Luly sold 35,000 shares of the stock in a transaction that occurred on Friday, July 6th. The shares were sold at an average price of $125.24, for a total value of $4,383,400.00. Following the sale, the insider now directly owns 625,049 shares in the company, valued at approximately $78,281,136.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Treasurer Paul J. Mellett sold 15,000 shares of the stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $120.57, for a total transaction of $1,808,550.00. Following the completion of the sale, the treasurer now owns 88,158 shares in the company, valued at $10,629,210.06. The disclosure for this sale can be found here. Insiders sold a total of 63,355 shares of company stock worth $7,682,559 over the last quarter. 10.56% of the stock is currently owned by corporate insiders.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.

Featured Story: Average Daily Trade Volume Explained

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.